APOL1 Nephropathy: From Genetics to Clinical Applications.
Friedman DJ, Pollak MR.
Clin J Am Soc Nephrol. 2021 Feb 8;16(2):294-303. doi: 10.2215/CJN.15161219. Epub 2020 Jul 2.
Abnormal lipoprotein metabolism in diabetic nephropathy.
Hirano T.
Clin Exp Nephrol. 2014 Apr;18(2):206-9. doi: 10.1007/s10157-013-0880-y. Epub 2013 Oct 17.
Lipoprotein abnormalities in diabetic nephropathy.
Hirano T.
Kidney Int Suppl. 1999 Jul;71:S22-4. doi: 10.1046/j.1523-1755.1999.07106.x.
Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes.
Li M, Wang Y, Yao Q, Liang Q, Zhang Y, Wang X, Li Q, Qiang W, Yang J, Shi B, He M.
Front Endocrinol (Lausanne). 2024 Jan 15;14:1337469. doi: 10.3389/fendo.2023.1337469. eCollection 2023.
Lipoprotein glomerulopathy in China.
Chen Y.
Clin Exp Nephrol. 2014 Apr;18(2):218-9. doi: 10.1007/s10157-013-0873-x. Epub 2013 Oct 29.
Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.
Szymanski JM, Waldman M, Conry-Cantilena C, West KA.
J Clin Apher. 2019 Aug;34(4):495-498. doi: 10.1002/jca.21677. Epub 2018 Dec 10.
Monocyte to High-Density Lipoprotein Ratio and Contrast-Induced Nephropathy.
Karanfil M, Yayla Ç, Ertem AG, Unal S, Açar B.
Angiology. 2018 Nov;69(10):917. doi: 10.1177/0003319718782537. Epub 2018 Jun 18.
Topics in lipoprotein glomerulopathy: an overview.
Saito T, Matsunaga A, Ito K, Nakashima H.
Clin Exp Nephrol. 2014 Apr;18(2):214-7. doi: 10.1007/s10157-013-0887-4. Epub 2013 Oct 23.
A case of lipoprotein glomerulopathy in a Greek Caucasian male.
Marinaki S, Kalaitzakis E, Kolovou K, Gakiopoulou H, Stylianou K, Papasotiriou M, Boletis IN.
Int Urol Nephrol. 2022 Apr;54(4):969-970. doi: 10.1007/s11255-021-02930-7. Epub 2021 Jun 23.
Atherogenic lipoprotein changes in diabetic nephropathy.
Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T, Ishimura E, Inaba M, Okuno Y, Nishizawa Y.
Atherosclerosis. 2001 Jun;156(2):425-33. doi: 10.1016/s0021-9150(00)00673-0.
